Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 9/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | CTSS | P25774 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | CTSK | P43235 | 5/20 | 0.51 |
| ▸ | CTSL | P07711 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7342473 | 1.00 | CACNA1B (0.60) | CACNA1BGAACTSSPOLBMAPT | |
| SCHEMBL7037594 | 1.00 | CACNA1B (0.60) | CACNA1BGAACTSSPOLBMAPT | |
| SCHEMBL7340561 | 0.89 | GAA (0.56) | CACNA1BGAACTSSPOLBMAPT | |
| SCHEMBL7340556 | 0.89 | GAA (0.56) | CACNA1BGAACTSSPOLBMAPT | |
| SCHEMBL7338159 | 0.87 | GAA (0.73) | CACNA1BGAACTSSPOLBMAPT | |
| SCHEMBL7337674 | 0.87 | GAA (0.73) | CACNA1BGAACTSSPOLBMAPT | |
| SCHEMBL7324099 | 0.86 | POLB (0.60) | GAAPOLBMAPTTDP1 | |
| SCHEMBL7337799 | 0.86 | POLB (0.60) | GAAPOLBMAPTTDP1 | |
| SCHEMBL7337804 | 0.86 | POLB (0.60) | GAAPOLBMAPTTDP1 | |
| SCHEMBL27347757 | 0.86 | POLB (0.60) | GAAPOLBMAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030060632-A1 | Calcium channel blockers | HU LAIN-YEN (US) | 2003-03-27 | — | — | US | disclosed |
| US-6495715-B2 | STROKE, ANTIISCHEMIC AGENTS, TRAUMAS, ANTIEPILEPIC AGENTS | WARNER-LAMBERT COMPANY | 2002-12-17 | — | — | US | disclosed |
| US-6458781-B1 | BLOCKERS CALCIUM CHANNEL ANTAGONISTS FOR STROKES, BRAIN DISORDERS | WARNER-LAMBERT COMPANY | 2002-10-01 | — | — | US | disclosed |
| US-6423689-B1 | Peptidyl calcium channel blockers | WARNER-LAMBERT COMPANY | 2002-07-23 | — | — | US | disclosed |
| US-6362174-B1 | ANALGESICS, ANTIISCHEMIC AGENTS, ANTIEOILEPTIC AGENTS | WARNER-LAMBERT COMPANY | 2002-03-26 | — | — | US | disclosed |
| US-20020028801-A1 | Reduced dipeptide analogues as calcium channel antagonitsts | RAFFERTY MICHAEL FRANCIS (US) | 2002-03-07 | — | — | US | disclosed |
| US-6316440-B1 | TREATMENT OF STROKE, HEAD TRAUMA, CEREBRAL ISCHEMIA, PAIN AND EPILEPSY | WARNER-LAMBERT COMPANY | 2001-11-13 | — | — | US | disclosed |
| US-20010023249-A1 | Calcium channel blockers | HU LAIN-YEN (US) | 2001-09-20 | — | — | US | disclosed |
| US-6251918-B1 | FOR THERAPY OF STROKE, CEREBRAL ISCHEMIA, HEAD TRAUMA, OR EPILEPSY | WARNER-LAMBERT COMPANY | 2001-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010023249-A1 | Calcium channel blockers | CACNA1I, CACNA1B, CACNA1G | CACNA1B 2/4885GAA 1903/4885CTSS 1250/4885 |
| US-20020028801-A1 | Reduced dipeptide analogues as calcium channel antagonitsts | CACNA1E, RYR1, CACNA1B | CACNA1B 3/4885GAA 4740/4885CTSS 2158/4885 |
| US-20030060632-A1 | Calcium channel blockers | CACNA1I, CACNA1B, CACNA1G | CACNA1B 2/4885GAA 1903/4885CTSS 1250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.